Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
NCT07573163Phase 2Recruiting
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tirzepatide in Autonomous Cortisol Secretion (ACS) (2 arms). Primary endpoint: Change in systolic blood pressure at 12 months. Started Jul 2026; status: recruiting.
02
Drugs
03
Conditions
Autonomous Cortisol Secretion (ACS)
Beyond the preview
Go deeper on NCT07573163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07573163.